Fundz

Who to call at 4D Molecular Therapeutics, Inc., and when

Fundz watches for the moments 4D Molecular Therapeutics, Inc. starts buying, and tells you who to reach.

  • An alert the day 4D Molecular Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at 4D Molecular Therapeutics, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at 4D Molecular Therapeutics, Inc.. With Fundz connected, it knows.

See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2
Back to SEC Filings
Executive ChangeItem 5.02 · 8-KMEDIUM RiskPositive

4D Molecular Therapeutics, Inc.

A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.

4dmoleculartherapeutics.com
Filed: Nov 17, 2025CIK: 0001650648Biotechnology
Full company profileView on SEC.gov

2 executive changes at 4D Molecular Therapeutics in the last 90 days. Clusters like this usually mean more senior seats open over the next few months.

See every company with multiple executive changes →

AI Executive Summary

AI-powered analysis of 8-K filing content

4D Molecular Therapeutics appointed Kristian Humer as Chief Financial Officer and Principal Financial Officer effective November 17, 2025, with a $520,000 base salary, a 40% bonus target, options on 480,000 shares, and a $100,000 sign-on bonus. The change fills the CFO seat and brings in an executive with prior CFO experience at Foghorn Therapeutics.

Key Takeaways

Kristian Humer, age 50, joined 4D Molecular Therapeutics as CFO and Principal Financial Officer on November 17, 2025, filling the finance leadership role.

Humer previously served as CFO of Foghorn Therapeutics from April 2024 to November 2025, a directly relevant public-biotech finance role.

3 more takeaways

Related Filings (9)

9 more filings from 4D Molecular Therapeutics, Inc. in the last 90 days

Filing Overview

Form Type8-K
Filing DateNov 17, 2025
Item5.02
CategoryExecutive Change
CIK0001650648
Accession #0001193125-25-283861
Risk LevelMEDIUM
SentimentPositive
Signalinformational
Topics
executive hireleadership transition

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings

4D Molecular Therapeutics, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

4 screens from a live account. No signup.